Clinical evaluation of the Novacor totally implantable ventricular assist system. Current status.
The totally implantable Novacor left ventricular assist system (LVAS) is currently approaching clinical evaluation. In vivo testing and production are underway with National Institutes of Health (NIH) support. Activity over the past year has focused on manufacturing engineering, preproduction quality assurance, and in vivo experiment completion. Subsequent to successful completion of the NIH-sponsored, 2-year preclinical device readiness test (DRT), a number of refinements were identified and approved by the NIH technical/data review board. Most of these were necessitated by obsolescence or unavailability of electronic components and the decision to use only high reliability military (MIL) qualified electronic components and processes. A few additional refinements were identified to increase design margins, all of which were qualified by accelerated testing. The development of production processes, automated test programs, and MIL compliant environmental stress screening procedures was completed. Production of LVAS subsystems, including core electronic components (hybrids, application-specific integrated circuits, and surface mount boards), was initiated. Animal studies are underway. The clinical trial, at Presbyterian-University Hospital of Pittsburgh and St. Louis University Medical Center, awaits completion of in vivo experiments, protocol development, and Food and Drug Administration approval.
Daniel
M A
MA
Novacor Division, Baxter Healthcare Corporation, Oakland, California 94621.
Lee
J
J
LaForge
D H
DH
Chen
H
H
Billich
J
J
Miller
P J
PJ
Ramasamy
N
N
Strauss
L R
LR
Jassawalla
J S
JS
Portner
P M
PM
D011211:Electric Power Supplies; D004869:Equipment Safety; D006354:Heart, Artificial; D006353:Heart-Assist Devices; D006801:Humans; D009316:National Institutes of Health (U.S.); D011474:Prosthesis Design; D014481:United States